
A year is both a very long time, and no time at all.
Dinner time

Optimist. He/Him. 🧬

A year is both a very long time, and no time at all.
Dinner time

Unpopular opinion: the people getting the most out of AI are the ones who could do the work without it.

With that all said, I’d like to thank my wonderful co-authors Natalie Tan, Pei Dai, Clair Sullivan, @ZornitzaS, Lata Vadlamudi and Nic Waddell (@TeamNicWaddell) - it was an absolute pleasure to work on this with all of you!

As a quick aside, I really like this figure which shows how re-analysis drives new molecular diagnoses. It views the excellent work from Dai et. Al (2023) and through the mechanisms we described in our paper from the same year

That said, most of these recommendations are pretty general and could benefit many other conditions with a genetic component.

We focused on epilepsy because the number of genes associated with it is increasing much faster than other conditions, and a molecular diagnosis can really help people.

For the final chapter of my PhD thesis, I managed to get the authors of some of my favourite re-analysis papers to work together to outline some recommendations to help neurologists decide when to re-analyse existing genetic data from epilepsy patients.

Re-analysing existing genomic data has the potential to give more patients a molecular diagnosis. Re-analysis is great - but it can be tricky to implement. 🧵 gimopen.org/article/S2949-77…

I'm almost tired of tweeting cancer progress this year but pancreatic cancer is getting smacked: Two pills, zero chemo, and 18 out of 22 patients saw their tumors shrink Tango paired its pill with daraxonrasib, the RAS pill FDA approved in August after it doubled survival vs chemo (13.2 vs 6.7 months) Most of these patients were already on their THIRD line of treatment, which is usually where the options run out 82% had their tumors shrink. Every single one had the cancer stop growing or shrink. 88% still hadn't progressed at 9 months Main side effects were mouth sores and rash, which compared to pancreatic chemo is kinda a spa day lol Only works on a subtype missing a gene called MTAP(not every pancreatic cancer), and a phase 3 vs chemo starts next year Your grandpa got 6 months and a hospice brochure. Our kids are gonna get two pills and a follow-up scan.

Hi everyone, I’ve finally had a free moment, so I’ve jumped on the bluesky train. I’m there as: alan-alan-alan

👉 Out now @NatureRevGenet: we CAN and we SHOULD do more to enable #genomic data sharing! 🧬🌏 👉Best practice examples and 12 actions we can all take together 👉 rdcu.be/dWfsu @GA4GH @AusGenomics @GenomicsEngland @NHSgms @AllofUsResearch @uk_biobank @ukfuturehealth

It was a lifetime ago, but I still have a lot of thoughts & feelings about my PhD/MPhil downgrade in 2012. Maybe there are lessons others can take from my journey (Failing Confirmation vs. Thesis Accepted Without Revision). I might write something in future - but not tonight.

So, I’d like to thank my wife and baby for putting up with / continuing to endure all my nonsense. Even though this project was a lot easier for me than my MPhil, these things are never easy for the student’s loved ones, and I feel like their sacrifices are often overlooked.

Many other people deserve to be thanked for so many different things. Andrew Mallett (@AndrewMallett8), Keith McNeil, and Lata Vadlamudi spring to mind. As do my friends in re-analysis, Natalie Tan and Pei Dai - but I feel like I’ve already gone for too long.

While I’ve never been entirely comfortable with the ‘Clinical Excellence Scholars’ title, I can attest that both Sam and Graeme are excellent people and excellent scholars. Going through everything with them, made life a lot easier

I was also very fortunate to share my PhD journey with two other brilliant people / PhD students: Graeme Mattison (@gcmattison) and Sam Robertson(@SamTRobertson1).